Talphera (TLPH) Stock Price, News & Analysis

Company Overview

Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for the management of acute pain. The company’s products are designed for use in medically supervised settings, including hospitals and other healthcare environments where rapid, noninvasive pain relief may be needed.

Talphera’s principal product is DSUVIA, a sublingual tablet containing sufentanil. The product was approved by the U.S. Food and Drug Administration in 2018 for the management of acute pain in adults in certified medically supervised healthcare settings. DSUVIA is administered under the supervision of a healthcare professional and is intended for short-term use when an intravenous route is not practical.

The company was formerly known as AcelRx Pharmaceuticals, Inc. and adopted the Talphera name as part of its focus on acute-pain therapies. Its operations and regulatory activities have primarily centered on the United States, with earlier development and commercialization efforts also involving Europe. Talphera is headquartered in the United States and has been led by Vincent Angotti as chief executive officer.

Key Stats

• Today's Range: $1.07 to $1.09
• 50-Day Range: $1.05 to $1.47
• 52-Week Range: $0.69 to $1.57
• Volume: 64,653 shs
• Average Volume: 163,919 shs
• Market Capitalization: $56.06 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Hold

Talphera Stock Analysis - MarketRank™

Talphera scored higher than 32% of companies evaluated by MarketBeat, and ranked 756th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Hold

Consensus Rating

Talphera has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Talphera has a consensus price target of $3.00, representing about 177.8% upside from its current price of $1.08.

Amount of Analyst Coverage

Talphera has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Talphera are expected to decrease in the coming year, from ($0.23) to ($0.27) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Talphera is -4.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Talphera is -4.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Talphera has a P/B Ratio of 2.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

1.44% of the float of Talphera has been sold short.

Short Interest Ratio / Days to Cover

Talphera has a short interest ratio ("days to cover") of 6.32.

Change versus previous month

Short interest in Talphera has recently increased by 2.97%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Talphera does not currently pay a dividend.

Dividend Growth

Talphera does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Talphera this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added Talphera to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Talphera insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.50% of the stock of Talphera is held by insiders.

Percentage Held by Institutions

37.67% of the stock of Talphera is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/10/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:TLPH
• Previous Symbol: NASDAQ:TLPH
• CIK: 1427925
• Web: talphera.com
• Phone: 650-216-3500
• Fax: 650-216-6500
• Employees: 12
• Year Founded: 2005

Price Target and Rating

• Average Price Target for Talphera: $3.00
• High Price Target: $3.00
• Low Price Target: $3.00
• Potential Upside/Downside: +177.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.29 million
• Net Margins: N/A
• Pretax Margin: -1,507,599.88%
• Return on Equity: -87.28%
• Return on Assets: -51.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.29
• Quick Ratio: 4.29

Sales & Book Value

• Annual Sales: $1 thousand
• Price / Sales: 56,058.48
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.37 per share
• Price / Book: 2.92

Miscellaneous

• Outstanding Shares: 51,906,000
• Free Float: 50,089,000
• Market Cap: $56.06 million
• Optionable: Optionable
• Beta: 0.67